Every 10-Q that Milestone Scientific, Inc. (MLSS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MLSS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MLSS filings page.
Milestone Scientific Inc. reported higher sales but continued losses for the three and six months ended June 30, 2026. Net product sales were $2.84 million for the quarter and $5.00 million year-to-date, up from $2.32 million and $4.56 million in 2025, driven mainly by Dental segment growth and renewed sales into China, plus early-stage growth in Medical CompuFlo® epidural systems.
Gross profit rose to $1.91 million for the quarter and $3.47 million for six months, with gross margin of about 67.2%, slightly below the prior year due to mix and higher product costs, including tariffs. Operating expenses declined to $5.36 million for six months from $6.75 million, reflecting lower regulatory, consulting and R&D spend, partially offset by higher stock-based compensation, royalties and marketing.
The company recorded a six‑month net loss of $1.90 million, improved from a $3.48 million loss a year earlier, but has an accumulated deficit of $135.7 million. Cash and cash equivalents were $2.07 million and working capital about $3.7 million at June 30, 2026. A $1.81 million April 2026 private placement and related warrants strengthened liquidity, yet management states that recurring losses, negative operating cash flows and limited cash raise substantial doubt about the ability to continue as a going concern without additional revenue growth or financing.
Milestone Scientific reported first-quarter 2026 product sales of $2.16 million, down slightly from $2.23 million a year earlier, as lower international dental demand and no revenue from China offset strong growth in medical products. Dental revenue declined about 6%, while medical revenue roughly doubled to $0.11 million.
Gross margin remained high at about 72%. The net loss narrowed to $0.84 million from $1.99 million on sharply lower operating expenses, including a pause in research and development spending. Operating cash flow turned positive at $0.09 million, and cash stood at $1.19 million with working capital of roughly $2.5 million as of March 31, 2026.
Despite this improvement, the company has an accumulated deficit of about $134.6 million and continues to disclose substantial doubt about its ability to continue as a going concern. In April 2026 it completed a private placement of 7,962,963 units at $0.27 per unit, raising about $2.15 million in gross proceeds and partially reducing related-party convertible notes, with additional dilution possible from attached three-year warrants. Milestone also remains below NYSE American stockholders’ equity listing thresholds and faces a compliance deadline in April 2027.
Milestone Scientific Inc. reported Q3 2025 results, highlighting modest sales and continued losses alongside a going concern warning. Product sales, net were $2.36 million versus $2.51 million a year ago. Gross profit was $1.64 million, and the operating loss was $1.13 million, compared with a $1.47 million loss last year. Net loss was $1.15 million, or $0.01 per share.
Dental drove nearly all revenue ($2.32 million), while Medical contributed $41 thousand. Cash and cash equivalents were $1.35 million, with working capital of about $3.1 million as of September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern and plans to seek additional financing.
For the nine months, operating cash use was $2.69 million. The company issued $800,000 of unsecured, related‑party convertible notes in April 2025. E‑commerce accounted for 43% of Q3 net product sales. Shares outstanding were 78,628,913 as of November 12, 2025.